Remimazolam Anesthesia and Outcomes After Bladder Cancer Surgery
Compares remimazolam with propofol for anesthesia in adults having bladder cancer surgery.
Plain-language title generated from the registry record
Registry title: Impact of Remimazolam on Prognosis After Bladder Cancer Surgery
Key facts
- Where
- Beijin, Beijing, Guiyang, Nanjing, and Shanghai, ChinaSee the 6 sites
- Phase
- Phase 4
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 50 and 90 years old?
Source: NCT04532606, who can take part
Where in China
- Peking University First HospitalBeijin, ChinaTaking people
- Beijing Tsinghua Chang Gung HospitalBeijing, ChinaTaking people
- The Sixth Medical Center of PLA General HospitalBeijing, ChinaTaking people
- Guizhou Provincial People's HospitalGuiyang, ChinaTaking people
- Jiangsu Provincial People's HospitalNanjing, ChinaTaking people
- Shanghai 10th People's HospitalShanghai, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT04532606
- Record updated
- 30 July 2025
- Original description
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.Read full original descriptionShow less
Impact of Remimazolam Tosilate for General Anesthesia on Prognosis After Bladder Cancer Surgery: a Randomized Controlled Trial
Bladder cancer is one of the most common genitourinary cancers. Transurethral resection of bladder tumor (TURBT) is the standard therapy for nonmuscle invasive bladder cancer. However, patients after TURBT are at risk for recurrence and progression. Benzodiazepines are proved to inhibit proliferation of multiple types of cancer cells in vitro. Delirium is an acute onset and transient cerebral dysfunction and is associated with worse outcomes. Previous studies indicated that benzodiazepines increase incidence of postoperative delirium. Remimazolam is a new benzodiazepine with rapid onset and ultra-short activity. The aims of this study are to explore the impact of remimazolam for general anesthesia on emergency delirium and recurrence-free survival in patients undergoing bladder cancer surgery.
Inclusion: Age ≥50 years and <90 years; Preoperative diagnosis is non-muscle-invasive bladder cancer(Ta-T1); Scheduled to undergo transurethral resection of bladder tumor; Agree to participate, and provide written informed consent.
Exclusion: Emergent surgery; Use of benzodiazepines for 1 week within the last month before surgery; The purpose of surgery is to make a diagnosis or preoperative judgement is that tumor cannot be completely removed; Combined with other malignant tumors; Preoperative history of schizophrenia, epilepsy, parkinsonism or myasthenia gravis; Inability to communicate in the preoperative period due to coma, profound dementia, language barrier, or end-stage disease; Critical illness (preoperative American Society of Anesthesiologists physical status classification ≥IV), severe hepatic dysfunction (Child-Pugh class C), or severe renal dysfunction (undergoing dialysis before surgery); Refuse to participate.